Nanobiotix 2018 Annual Results - Seite 2

Other sales

Licences

 

Other revenues

Research Tax Credit

Subsidies

Other

  116

109

7

-

 

3,363

3,251

90

22

 

252

229

23

-

 

3,470

3,259

154

57

Research & Development (R&D) costs (incl.
Share-based payments)

(20,893) (17,733)

Selling, General and Administrative (SG&A)
costs (incl. Share-based payments)

  (12,653)   (11,254) Operating loss   (30,066)   (25,267) Financial loss   (277)   (876) Income tax   -   - Net loss for the period   (30,345)   (26,143)

_______________
¹ The Company’s statutory auditors have completed their audit work on the 2018 financial statements and expect to issue their audit report on March 20^th, 2019.

Financial Review (unaudited)²

Total Revenue in 2018 amounted to €3.5M vs. €3.7M in 2017, mainly due to:

• Revenues related to services provided mainly by the Company to its partner, PharmaEngine, pursuant to a commercial agreement, amounted to €116K in 2018 (vs. €252K in 2017); and
• Other revenues of €3,363K in 2018 (vs. €3,469K in 2017) mainly related to the Research Tax Credit (Crédit d’Impôt Recherche - CIR).

Total Operating expenses reached €33.5M in 2018 vs. €29.0M in 2017: